日本化学療法学会雑誌第54巻第S-1号

Size: px
Start display at page:

Download "日本化学療法学会雑誌第54巻第S-1号"

Transcription

1 β β β Key words β β I

2 HP- -CD CHR RHC R R R R CHR R R R R RHC R R R CHR R R R RHC CHR R H CH CH Fig.. Structuralformulaofhydroxypropyl-β -cyclodextrin(hp-β -CD). CH n H β β β β

3 Table-. Dosageandadministration(Singleadministrationstudy) Step Drug(Dosage) Volume Administration n -S(00mg/g) 0mL fastingorfed Placebo(g) 0mL -S(00mg/g) 0mL Placebo(g) 0mL -S(00mg/g) 0mL fasting Placebo(g) 0mL -S(00mg/g) 0mL Placebo(g) 0mL Dosage:-S(Itraconazole:mg/HP-β -CD:g)orPlacebo(HP-β -CD:g) Step Table-. Dosageandadministration(Repeatedadministrationstudy) Drug(Dosage) -S(00mg/g) Placebo(g) -S(00mg/g) Placebo(g) Volume 0mL 0mL 0mL 0mL Administration oncedailyfor daysfasting Dosage:-S(Itraconazole:mg/HP-β -CD:g)orPlacebo(HP-β -CD:g) n 7 7 Table-. Background characteristics(singleadministration study) Table-. Backgroundcharacteristics(Repeatedadministrationstudy) Step n Age Height(cm) Weight(kg) Step n Age Height(cm) Weight(kg) Total.0±..9±.5.±..±.5.±. (0-0) 9.±. 7.9±. 7.9±.9 7.±7. 7.7±5. (.-.) 59.9±.0.±.5.±.5.5±9..9±. (5.-.) Total ±..9±..±. (0-) 7.7±5. 7.±7. 7.±. (.-7.).±5..±9..7±. (5.-77.) Mean±S.D.(Min-Max) Mean±S.D.(Min-Max) II

4 Administration Meal Subjectivesymptom Medicalexamination Weight Bloodpressure, pulserate,temp -leadecg Laboratorytests ) Plasmadrugconcn Urinarydrugconcn Fecaldrugconcn ) Day Freetime Freetime 0 ) Table. Scheduleofsingleadministrationstudy Day 5 Day Timeafterstartofadministration 0 Day 0 Day 7 Day5 9 Folowup ) ) Hematology:WBC,WBCdiferential,RBC,hemoglobin,hematocrit,meancorpuscularvolume(MCV),meancorpuscularhemoglobin(MCH), meancorpuscularhemoglobinconcentration(mchc),plateletcount Bloodbiochemistry:glucose,totalprotein,albumin,A/G,triglyceride,totalcholesterol,Cr,BUN,uricacid,totalbilirubin,directbilirubin, GT,GPT,guanase,lactatedehydrogenase,γ -GTP,ALP,leucineaminopeptitase,creatinekinase,amylase,Na,K,Cl,C-reactiveprotein Urinalysis:specificgravity,sediment,protein,glucose,urobilinogen,bilirubin,pH,occultblood,ketonebody ) Steponly ) Step:fedgrouphavebreakfastat:0 ) weekafteradministration µ β β µ β β

5 Administration Meal Subjectivesymptom Medicalexamination Weight Bloodpressure, pulserate,temp -leadecg Laboratorytests ) Plasmadrugconcn Day Table. Scheduleofrepeatedadministrationstudy Day Day- Timeafterstartofadministration ) Day7 Urinarydrugconcn ) 0- Administration Meal Subjectivesymptom Medicalexamination Weight Bloodpressure, pulserate,temp -leadecg Laboratorytests Plasmadrugconcn Urinarydrugconcn Day- Day Timeafterstartofadministration Day 0 Day Day Day Day ) ) ) Hematology:WBC,WBCdiferential,RBC,hemoglobin,hematocrit,meancorpuscularvolume(MCV),meancorpuscularhemoglobin(MCH), meancorpuscularhemoglobinconcentration(mchc),plateletcount Bloodchemistry:glucose,totalprotein,albumin,A/G,triglyceride,totalcholesterol,HDL-cholesterol,Phospholipid,Cr,BUN,uricacid,total bilirubin,directbilirubin,gt,gpt,guanase,lactatedehydrogenase,γ -GTP,ALP,leucineaminopeptitase,creatinekinase,amylase,Na,K, Cl,C-reactiveprotein Urinalysis:specificgravity,sediment,protein,glucose,urobilinogen,bilirubin,pH,occultblood,ketonebody ) Dayonly ) Day:0-,- ) Day0only β β µ β β β β β β

6 ng ml,000 Fasting Fed H- Plasma concentration 00 0 Mean S.D. n Time h Fasting n Fed n H- H- Cmax ng ml Tmax h t h AUCinf ng h ml, ,055.,7.,57.0,09.0 5,75.7,0. Mean S. D. Fig.. Efectoffoodonplasmaconcentrationafteradministrationofsingledose(00mg)ofItraconazoleoralsolution. β β β β β β β β β β β β β

7 ng ml 0,000 Plasma concentration, S 0 ml 0 ml 0 ml 0 ml Mean S.D. n ng ml Time h 0,000 -S H- Plasma concentration, ml 0 ml 0 ml 0 ml Mean S.D. n Time h -S Cmax ng ml Tmax h t h AUCinf ng h ml 0 ml n 0 ml n 0 ml n 0 ml n H- H- H- H ,00. 0., ,. 9.0,.5.0, , ,055.,7. 7,9.,7.7 9,07.7,7.,9.,7.9,. 7,.9,7.7,.,0.,99.0 Mean S. D. Fig.. PlasmaconcentrationafteradministrationofsingledoseofItraconazoleoralsolution. III

8 ng ml 0,000 -S H- 0 ml 0 ml,000 Plasma concentration 00 0 Mean S.D. n Day administration Time 0 00 h -S Cmax ng ml Tmax h t h AUC 0- ng h ml after 7 days 0 ml n 0 ml n H- H- 0 ml n H- after days 0 ml n H ,.., ,.0.9,0.0 9.,9.., , ,5.,79.,57.,.7,5. 5,0.7 5,. 9,97.,.,07.0 5,99.9,5.,9. 7,57. 59,5.5,99. Mean S. D. Fig.. PlasmaconcentrationdaysafteradministrationofItraconazoleoralsolution. Table5. Adverseeventsfindinginsingleadministrationstudy Step Drug Adverseevents Grade Relationofdrug -S(Fed) Probably -S0mL Rash,Itch -S0mL Rash,Itch Placebo -S0mL Nausea Diarhea Probably Total-bilirubin Direct-bilirubin Probably

9 Table. Adverseeventsfindinginrepeatedadministrationstudy Step Drug Adverseevents Grade Relationofdrug -S0mL Sediment-WBC Placebo Abdominaldispleasure Myalgia Intercostaltenderness Sediment-WBC -S0mL Headache Headache Total-Cholesterol Probably Probably Rightmammarytenderness Probably Placebo Pharyngalgia Cough Pharyngealredness Table7. PharmacokineticsofItraconazoleoralsolutionvs.capsulesinhealthyvolunteersafteradministrationofsingledose(00mg) Cmax(ng/mL) Tmax(h) T/(h) AUC ) (ng h/ml) -S(n= ) fasting fed H- H- 09.9±. 59.5±7.5 5.±..±0.0.±0..5±0..±..±..± ±..± ±.,.7± 70. 7,055.±,7.,57.0±,09.0 5,75.7±,0. -Cap(n= 5) fasting fed H- H- 5.±.5.±0..±0.7 7.±7..±0.9.±0.9.±..0±..± ±.0.9± ±., ± 57, ±,, ±,,77 ±, ) -S:AUCinf,-Cap:AUC0- Mean±S.D. Table. PharmacokineticsofItraconazoleoralsolutionvs.capsulesinhealthyvolunteers(after7or daysadministrationof00mg/day) Cmax(ng/mL) AUC ) (ng h/ml) Tmax(h) -S 7days 97.±5.9 0,5±,79.0±0. -Cap days.±.,±,90.±0. -S/-Cap.. ) -S:AUC0-,-Cap:AUC0- Mean±S.D. β

10 Table9. TroughplasmaconcentrationdaysafteradministrationofItraconazoleoralsolution -S Day 00mg H- -S Day 00mg H-. ±. 9.5 ± ±5.. ±9.. ±. 77. ±7.0.5 ± ±00.9. ±.. ± ± ± ± ± ±.5,5. ± ±.7.9 ±. 55. ±.,. ±7. 7. ± ±. 7. ±9.,. ± ±. 7.5 ± ±5.,0. ± ± ± ±5.0,0. ± ± ± ±7.,0. ±5.7. ± ± ±0.7,7. ± ± ±.7,0. ±.,0. ±. 7.5 ± ±9.,0. ±.0,507. ±7. µ µ µ µ β β β β β β β β

11 ng/ml S alone -S meprazole Plasma concentration Mean S.D. n Time h ng ml 50 H- -S alone 00 -S meprazole 50 Plasma concentration Mean S.D. n Time h -S alone n -S meprazole n Janssen Pharmaceutica data H- H- Cmax ng ml Tmax h t h AUC ng h ml ,5 5 5,5,0,979 5,5,09 Mean S. D. Fig.5. EfectofmeprazoleonplasmaconcentrationofItraconazoleoralsolution. β β β β

12 β in vitro in vivo β β β

日本化学療法学会雑誌第57巻第S-2号

日本化学療法学会雑誌第57巻第S-2号 µ µ Key words µ µ µ I Table1. Subjectprofilesin(A)singleand(B)multiple-dosestudies (A)Single-dosestudy Age (yr) Height (cm) Bodyweight (kg) BMI (kg/m ) Ccr(Cockcroft) (ml/min) Ethnicity dose(mg) n 5 5.1±.,3

More information

日本化学療法学会雑誌第54巻第S-1号

日本化学療法学会雑誌第54巻第S-1号 β β Key words β Candida krusei Candida glabrata β I β Drugadministration Baselinecharacteristics Clinicalsymptom Mycologicaltests Plasmadrugconcn Adverseevents Laboratorytests ) -leadecg Clinicalphotograph

More information

日本化学療法学会雑誌第57巻第5号

日本化学療法学会雑誌第57巻第5号 in vitro Key words Streptococcus pneumoniae β Haemophilus influenzae Escherichia coli I Table. Antibacteriallevofloxacinactivityagainstclinicalisolates Organism Year Susceptibility(%)(Numberofstrains)

More information

CTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11

More information

日本化学療法学会雑誌第51巻第2号

日本化学療法学会雑誌第51巻第2号 piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC

More information

日本化学療法学会雑誌第59巻第5号

日本化学療法学会雑誌第59巻第5号 Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.

More information

O1-1 O1-2 O1-3 O1-4 O1-5 O1-6

O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35

More information

日本化学療法学会雑誌第54巻第1号

日本化学療法学会雑誌第54巻第1号 Chlamydophila pneumoniae Chlamydophila psittaci Mycoplasma pneumoniae Legionella pneumophila C. pneumoniae C. psittaci C. pneumoniae C. psittaci M. pneumoniae M. pneumoniae C. psittaci L. pneumophila C.

More information

日本化学療法学会雑誌第61巻第4号

日本化学療法学会雑誌第61巻第4号 μ μ μ μ μ μ Key words I β μ Sex Age (years) Height (cm) Evaluation items Table1.Characteristics of patients 1. mg/kg/day (n14) 2.5 mg/kg/day (n9) 5. mg/kg/day (n9) Total (n32) male 12 8 7 27 female 2 1

More information

日本化学療法学会雑誌第56巻第1号

日本化学療法学会雑誌第56巻第1号 β β β β β Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalismycoplasma pneumoniaechlamydia pneumoniae β Key wordsβ mys nilc laci ngis Table. Assessmentschedule Parameters Patientcharacteristics

More information

立命館21_松本先生.indd

立命館21_松本先生.indd 2143-552010 1 2 () 1 2 3 456 78- Key Words 1 3 12007 2 3 508 19992008 1 23 4 43 2120107 4 2008 1992 2003 2005 1989 2008 4 2 2-1 10 4 4 6 5 4 5 2946 1 155 11 41 44 45 4 2-2 2003 1 21 2 1 3 4 5 6 7 3 2120107

More information

立命館20_服部先生.indd

立命館20_服部先生.indd 20 93-105 2010 2 () ' - 1 ( ) ( ' 2005) Key Words 2 1967 93 20 2010 1 94 1 ' 2002 2 2 1996 1996 1999 2 2 2 1993 1999 4 1 2 1985 1989 1986 1994 4 1 2 1 1 4 2 4 4 1 4 1966 4 10-1970 20 1993-1972 95 20 2010

More information

1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70

1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70 14 2006 1 Key Words 2002 3 1 2 3 3 1 2 3 1969 1987 69 1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70 14 2006 1 15 71 72 1 22 6 32 9 200 6 3 1 2 2000 10 1 2003 10 2005 6 5 4

More information

立命館16_坂下.indd

立命館16_坂下.indd 1669-792008 1 - ' 85- -108 ' Key words 1 2 2003 69 1620082 5 3 1990 1997 4 5 2001 1307 6 7 1 1 1 1996 100 2 1997 71 3 1998 71 4 1999 96 5 2000 95 6 2001 145 7 2002 191 8 2003 174 9 2004 120 10 2005 122

More information

立命館人間科学研究No.10

立命館人間科学研究No.10 1 77 5 Key words 1 23 3 11417 14310045 20022004 2 2003 20022005 20022004 2 10200511 3 2003 1152003 59 1995 3 32003 19932002 20032003 2005 20052005 4 1997 2000521986 2001 42001 3 1981 6 1 7 5 1000248 1632647

More information

立命館21_川端先生.indd

立命館21_川端先生.indd 21 119-132 2010 ( ) ' Key Words 119 21 2010 7 1962 2001 2001 2007 1982 1988 1997 2007 1997 1998 1863 1880 1 1998 1998 2001 1599 120 121 1599 1695 8 1695 1714 4 1714 1715 5 1715 100 1812 9 1812 1864 2001

More information

立命館14_前田.indd

立命館14_前田.indd 1499-1122007 1 ) ) ) ) ) (1) -- ) ) ) ) ) ) ( ) ) ' ) ) ) ) - 1) 2)' 3) Key words 19811994 1721 99 1420073 100 20012004 2005 2004 2002 33 34 10 1987 45 20002003 2002 1 1 2000 1 1 2001 2 200341 12004 2

More information

立命館17_坂下.indd

立命館17_坂下.indd 1793-1052008 1 () -- -- - Key words 1 93 1720088 2 3 2003 15 1996 50 3040 2 3 4050 50 10 1980 1995 1950 1958 1968 1972 94 95 1987 4 4 70 3 3 1 2000 2001 4 1720088 96 2001 2003 2 1978 1990 1997 130 2 3

More information

立命館人間科学研究No.10

立命館人間科学研究No.10 49 00 7 Key words 980 995 50 0005 90 997 99 990 994 99 99 99990 99 996 988988 994 99 995 995 995 994 984 988 986 997 997 00 995 00 5 7 5 5 999 997 997 998 6 998 999 997 997 998 0040000 994 996 000 00 5

More information

立命館19_椎原他.indd

立命館19_椎原他.indd 191-132009 1 ( ) ' Key Words 1 11 12007 2007 200520062 201120062 7558 4009 1 1920098 2007 2 2000 028 2005 1999 12 1999 13 1968 2 3 '1992 2007 2001 20052001 1977 2005 2005 2007 21 21 22 461927 3 13 1920098

More information

立命館人間科学研究No.10

立命館人間科学研究No.10 61 10 1990 Key words 1 102005 11 62 2000 1 1920 10 1892 63 1 1 19 100 1914 100 1 1 20 1 2 102005 11 64 1946 21 4 1947 1949 1947 22 1 3 1956 1959 1958 2 1964 65 2 10 1975 7080 70 2 1 1987 1990 40 1989 1989

More information

立命館19_徳田.indd

立命館19_徳田.indd 1991-1022009 1 2 () )--) 28 2827 1 2 Key Words 1 (1721 2000 20012001 20082009 91 1920098 92 20042004 2004 2001 12 2005 20082009 2005 3 1997 200820096 2007 2 20082009 93 20012001 12 2008 2009 19611966 1

More information

I

I I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4

More information

CHEMOTHERAPY SEPT. 1991

CHEMOTHERAPY SEPT. 1991 CHEMOTHERAPY SEPT. 1991 VOL. 39 S-3 Table 1. Background of characteristics and allocation of 9 healthy male volunteers in a single-dose study on betamipron Table 2. Background of characteristics and allocation

More information

日本化学療法学会雑誌第58巻第2号

日本化学療法学会雑誌第58巻第2号 Key words β Candida Table1. MCFGCPAstudygroup Investigator (representative) YoshitsuguMiyazaki NaoyukiMiyashita RyoichiAmitani KenjiOgawa AtsuyukiKurashima ToshiroKiguchi MichiakiMishima YuichiInoue HiroshiSaito

More information

CHEMO THER APY Table 1. Background of the volunteers in the phase I clinical trial of ME1207 Table 2. Methods for Phase I clinical trial of ME1207 All doses are expressed in terms of potency as ME1206

More information

untitled

untitled 1% 1 mg 1 mg 2 CTD 6 Section 2.6.1 Introduction 2.6.1 H 1 descarboethoxyloratadinesch 34117 7.9 SCH 34117 2.6.1-1 O OC 2 H 5 Cl N N JAN Loratadine (JANINN) ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]

More information

20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472

More information

I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................

More information

- 2 -

- 2 - - 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -

More information

2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1

2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1 1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4

More information

1 (1) (2)

1 (1) (2) 1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)

More information

報告書 H22-2A-09

報告書 H22-2A-09 061-0293 1757 TEL 0133-23-1211 2.0% 0.5% in vitro QOL Quality of Life 1 MCE-400 400 mpa s Duck Algin 350M M/G 0.8 70 80 C 20% 50 C 1.0% 5 C SV-10 5 C 10 ml E TV 20H model E 1 34 R24 1 ml 5 C 30 6 12 30

More information

日本化学療法学会雑誌第56巻第3号

日本化学療法学会雑誌第56巻第3号 β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida

More information

日本化学療法学会雑誌第57巻第6号

日本化学療法学会雑誌第57巻第6号 Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae S. pneumoniae β β H. influenzae S. pneumoniae H. influenzae M. catarrhalis Key words Otalgia Fever Item Crying,Iritation,

More information

「産業上利用することができる発明」の審査の運用指針(案)

「産業上利用することができる発明」の審査の運用指針(案) 1 1.... 2 1.1... 2 2.... 4 2.1... 4 3.... 6 4.... 6 1 1 29 1 29 1 1 1. 2 1 1.1 (1) (2) (3) 1 (4) 2 4 1 2 2 3 4 31 12 5 7 2.2 (5) ( a ) ( b ) 1 3 2 ( c ) (6) 2. 2.1 2.1 (1) 4 ( i ) ( ii ) ( iii ) ( iv)

More information

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii

More information

エディロールカプセルインタビューフォーム

エディロールカプセルインタビューフォーム 2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/

More information

nsg02-13/ky045059301600033210

nsg02-13/ky045059301600033210 φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W

More information

研修コーナー

研修コーナー l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l

More information

日本化学療法学会雑誌第57巻第1号

日本化学療法学会雑誌第57巻第1号 In vitro Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli µs. pneumoniae E. coli µ Key words in vitrostreptococcus pneumoniae Escherichia coli Escherichia coli

More information

日本化学療法学会雑誌第55巻第S-1号

日本化学療法学会雑誌第55巻第S-1号 µ µ Key words Streptococcus pneu- moniae S. pneumoniae µ µ I γ H H C HN F F O N O CO H H C SO H H O Fig.. ChemicalstructureofGRNX. γ γ II Haemophilus influenzae Pseudomonas aeruginosa Streptococcus intermedius

More information

日本消化器外科学会雑誌第31巻第7号

日本消化器外科学会雑誌第31巻第7号 Key words: obstructive jaundice, biliary drainage, bile refeeding, hepatectomy Fig. 1 Animal models a: experiment I b: experiment 2 silicon tube Fig. 2 Experimantal design Sham Ope J - l r bile duct Zweeks

More information

VOL.39 S-3

VOL.39 S-3 VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose

More information

取扱説明書 [F-08D]

取扱説明書 [F-08D] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 a bc d a b c d 17 a b cd e a b c d e 18 19 20 21 22 a c b d 23 24 a b c a b c d e f g a b j k l m n o p q r s t u v h i c d e w 25 d e f g h i j k l m n o p q r s

More information

untitled

untitled 20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20

More information

第86回日本感染症学会総会学術集会後抄録(I)

第86回日本感染症学会総会学術集会後抄録(I) κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β

More information

日本化学療法学会雑誌第58巻第S-2号

日本化学療法学会雑誌第58巻第S-2号 μ Key words Streptococcus pneumoniae β Haemophilus influenzae β Moraxella Branhamella catarrhalis I F F H C SO H H O H N N N N F CO H O Fig.1. Chemicalstructureoftosufloxacintosilatehydrate. α Body weight

More information

Vol. 4, No

Vol. 4, No 1 0.005 71 2 0.005 72 3 0.005 73 4 0.005 74 5 0.005 KRM 75 6 0.005 76 7 0.005 77 8 0.005 78 9 0.005 79 10 0.005 80 11 0.005 TS 81 12 0.005 TOA 82 13 0.005 83 14 0.005 84 15 0.005 NS 85 16 0.005 86 17 0.005

More information

CHEMOTHERAPY APR. 1982

CHEMOTHERAPY APR. 1982 VOL.30 S-1 CHEMOTHERAPY Table 1 Dose of CTT and subjects i. v.: Intravenous bolus injection d. i. v.: Intravenous drip infusion i. m.: Intramuscular injection Fig. 1 Schedule for examination of CTT, 1.0g

More information

- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...

- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8... 取 扱 説 明 書 - - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...9...11 - - - - - - - - - - - - - - - - -

More information

untitled

untitled Data cleaning Original datan=8479 NCC/ptkgN=7958 NCC10x10E628 8139 NCC/kgPage 1-2) Covariate cleaningcovariate Page Page5-8 Kaplan-Meier method, Log-rank, Cox hazard model Overall survival Cumulative incidence

More information

1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)

1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2) 1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /

More information

Vol. 36, Special Issue, S 3 S 18 (2015) PK Phase I Introduction to Pharmacokinetic Analysis Focus on Phase I Study 1 2 Kazuro Ikawa 1 and Jun Tanaka 2

Vol. 36, Special Issue, S 3 S 18 (2015) PK Phase I Introduction to Pharmacokinetic Analysis Focus on Phase I Study 1 2 Kazuro Ikawa 1 and Jun Tanaka 2 Vol. 36, Special Issue, S 3 S 18 (2015) PK Phase I Introduction to Pharmacokinetic Analysis Focus on Phase I Study 1 2 Kazuro Ikawa 1 and Jun Tanaka 2 1 2 1 Department of Clinical Pharmacotherapy, Hiroshima

More information

200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3

More information

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2) (1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46

More information

P072-076.indd

P072-076.indd 3 STEP0 STEP1 STEP2 STEP3 STEP4 072 3STEP4 STEP3 STEP2 STEP1 STEP0 073 3 STEP0 STEP1 STEP2 STEP3 STEP4 074 3STEP4 STEP3 STEP2 STEP1 STEP0 075 3 STEP0 STEP1 STEP2 STEP3 STEP4 076 3STEP4 STEP3 STEP2 STEP1

More information